CAR-T cell therapy for active autoimmune disease flare-ups
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Immune system & allergy, Mouth & dental, Skin clinical trials.
This study tests an immune-cell treatment (CAR-T, called BRL-301) in people with certain autoimmune diseases that are active and hard to control. It may help your immune system calm down if standard treatments have not worked or your disease has returned.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 65.
- Your blood test shows CD19 on B cells (a specific immune cell marker).
- Your blood counts and major organs are in a safe range (bone marrow, liver, kidneys, and blood clotting).
- You have an active form of one of these diseases: lupus, Sjögren’s with low platelets, systemic sclerosis with lung involvement, inflammatory muscle disease, ANCA vasculitis, or antiphospholipid syndrome—meeting the study’s severity rules.
- You have tried standard treatments that either did not work or your disease came back.
- You can sign consent, follow study visits, and meet birth-control rules if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment for people with certain autoimmune diseases that have not responded to standard therapies. The treatment uses your own immune cells modified to target and attack disease-causing cells.
This trial tests a new type of immune cell therapy (CAR-T cells) for people with lupus that has not responded well to standard treatments. It aims to reset the immune system to reduce lupus activity.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to treat severe autoimmune diseases like lupus, scleroderma, vasculitis, muscle inflammation, and Sjögren's syndrome that haven't responded well to standard treatments. The therapy works by modifying your own immune cells to target and reduce the B cells driving your disease.
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
This trial tests if a special immune cell therapy (CAR-T) can help people with certain autoimmune diseases like lupus, Sjogren's syndrome, scleroderma, myositis, vasculitis, or antiphospholipid syndrome that haven't improved with standard treatments. It is a very early phase study to check safety and effectiveness.
Hear when a new Sjogren's Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.